Physician profile
Jaymie Reyes
NPI 1114379377
$4,614.70
in general payments reported to CMS, 2019-2025
25 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $630 · 2022: $1,321 · 2023: $1,527 · 2024: $992 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,642 · Education: $21.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,642.48 |
| Education | $21.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,928.43 | 2021-2024 | Airsupra, Breztri, Lokelma |
| Glaxosmithkline, LLC. | $875.10 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $385.54 | 2021-2024 | |
| Novo Nordisk INC | $324.54 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.92 | 2021-2023 | Jardiance |
| Ardelyx, INC. | $124.99 | 2025 | Ibsrela |
| Cardiovascular Systems INC. | $102.94 | 2021 | |
| Merck Sharp & Dohme LLC | $97.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $62.09 | 2021-2025 | Camzyos |
| Incyte Corporation | $61.55 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.14 | 2021-2022 | |
| Janssen Biotech, INC. | $45.26 | 2021-2024 | Imbruvica, Darzalex |
| Novartis Pharmaceuticals Corporation | $40.47 | 2021-2022 | |
| Pfizer INC. | $36.42 | 2023-2024 | |
| Amgen INC. | $32.46 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $27.90 | 2021-2022 | |
| Emmaus Medical, INC. | $23.08 | 2022 | |
| Daiichi Sankyo INC. | $21.26 | 2023 | Enhertu |
| Genentech USA, INC. | $16.65 | 2022 | |
| Astellas Pharma US INC | $15.00 | 2021 | |
| Array Biopharma INC | $13.51 | 2021 | |
| Sobi, INC | $13.50 | 2022 | |
| Lilly USA, LLC | $13.47 | 2022 | |
| Octapharma USA, INC. | $12.86 | 2022 | |
| Rigel Pharmaceuticals, INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaymie Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.